60872 Federal Register / Vol. 78, No. 191 / Wednesday, October 2, 2013 / Notices 

will not be disclosed except in 

accordance with procedures set forth in 

40 CFR part 2. 

2. Tips for preparing your comments. 

When submitting comments, remember 

to: 

i. Identify the document by docket ID 

number and other identifying 

information (subject heading, Federal 

Register date and page number). 

ii. Follow directions. The Agency may 

ask you to respond to specific questions 

or organize comments by referencing a 

Code of Federal Regulations (CFR) part 

or section number. 

iii. Explain why you agree or disagree; 

suggest alternatives and substitute 

language for your requested changes. 

iv. Describe any assumptions and 

provide any technical information and/ 

or data that you used. 

v. If you estimate potential costs or 

burdens, explain how you arrived at 

your estimate in sufficient detail to 

allow for it to be reproduced. 

vi. Provide specific examples to 

illustrate your concerns and suggest 

alternatives. 

vii. Explain your views as clearly as 

possible, avoiding the use of profanity 

or personal threats. 

viii. Make sure to submit your 

comments by the comment period 

deadline identified. 

3. Environmental justice. EPA seeks to 

achieve environmental justice, the fair 

treatment and meaningful involvement 

of any group, including minority and/or 

low income populations, in the 

development, implementation, and 

enforcement of environmental laws, 

regulations, and policies. To help 

address potential environmental justice 

issues, the Agency seeks information on 

any groups or segments of the 

population who, as a result of their 

location, cultural practices, or other 

factors, may have atypical or 

disproportionately high and adverse 

human health impacts or environmental 

effects from exposure to the pesticide(s) 

discussed in this document, compared 

to the general population. 

II. What action is the Agency taking? 

Under section 5 of the Federal 

Insecticide, Fungicide, and Rodenticide 

Act (FIFRA), 7 U.S.C. 136c, EPA can 

allow manufacturers to field test 

pesticides under development. 

Manufacturers are required to obtain an 

EUP before testing new pesticides or 

new uses of pesticides if they conduct 

experimental field tests on 10 acres or 

more of land or one acre or more of 

water. A copy of the applications and 

any information submitted is available 

for public review in the docket 

established for these EUP applications. 

Following the review of the application 

and any comments and data received in 

response to this solicitation, EPA will 

decide whether to issue or deny the EUP 

request, and if issued, the conditions 

under which it is to be conducted. Any 

issuance of an EUP will be announced 

in the Federal Register. 

Therefore, pursuant to 40 CFR 

172.11(a), the Agency has determined 

that the following EUP applications may 

be of regional and national significance, 

and therefore is seeking public comment 

on the following EUP applications: 

1. 524–EUP–RNA. (EPA–HQ–OPP– 

2013–0012). Submitter: Monsanto 

Company, 800 N. Lindbergh Blvd., St. 

Louis, MO 63167. Pesticide chemical: 

MON 102100. Type of chemical: 

Nematicide. Summary of request: Large 

scale seed treatment trials on corn, 

soybean, and cotton. 12.94 pounds (lb.) 

of active ingredient (a.i.) per year on 

corn seed, 19.10 lb. of a.i per year on 

soybeans seed, and 7.46 lb. of a.i. per 

year on cotton seed will be used in 208 

locations of 20 ft. x 1,000 ft. plots. 

Period of treatment is from February 1, 

2014, to December 31, 2016. Treated 

seed must be dyed to impart an 

unnatural color to prevent use for food, 

feed, or oil purposes. This is a cropdestruct EUP. 

2. 72500–EUP–E. (EPA–HQ–OPP– 

2013–0546). Submitter: Scimetrics Ltd. 

Corp., P.O. Box 1045, Wellington, CO 

80549. Pesticide chemical: Warfarin. 

Type of chemical: Rodenticide. 

Summary of request: Authorization 

requested to use 0.005% warfarin bait 

blocks at one or more test sites in large, 

fenced areas in Texas. 0.63 lb of 

warfarin in 12,600 lb of formulated bait. 

Bait to be applied on 25 lb to 100 lb 

amounts in dispensers said to allow 

feral hogs to access bait while limiting 

access by nontarget species. Area 

covered by treatments not to exceed 

2,471 acres (10 km3). Baiting period is 

projected to last 3 weeks, with 

dispensers being replenished ‘‘as 

needed.’’ Proposed period of treatment 

is from July 1, 2014, to August 31, 2014. 

List of Subjects 

Environmental protection, 

Experimental use permits. 

Dated: September 23, 2013. 

Daniel J. Rosenblatt, 

Acting Director, Registration Division, Office 

of Pesticide Programs. 

[FR Doc. 2013–23947 Filed 10–1–13; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL FINANCIAL INSTITUTIONS 

EXAMINATION COUNCIL 

[Docket No. AS13–22] 

Appraisal Subcommittee Meeting 

AGENCY: Appraisal Subcommittee of the 

Federal Financial Institutions 

Examination Council. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with Section 

1104(b) of Title XI of the Financial 

Institutions Reform, Recovery, and 

Enforcement Act of 1989, as amended, 

notice is hereby given that the Appraisal 

Subcommittee (ASC) will meet in open 

session for its regular meeting: 

DATES: October 9, 2013. 

ADDRESSES: 400 7th Street SW., 

Washington, DC 20024. 

SUPPLEMENTARY INFORMATION: 

Location: OCC—400 7th Street SW., 

Washington, DC 20024 

Date: October 9, 2013 

Time: 10:30 a.m. 

Status: Open 

Matters To Be Considered 

Summary Agenda 

September 11, 2013 minutes—Open 

Session 

(No substantive discussion of the 

above items is anticipated. These 

matters will be resolved with a single 

vote unless a member of the ASC 

requests that an item be moved to the 

discussion agenda.) 

Discussion Agenda 

Appraisal Foundation May, June and 

July 2013 Grant Reimbursement 

Requests 

Phase 2 Appraisal Complaint Hotline 

Recommendations 

Mississippi and South Carolina 

Compliance Reviews 

How To Attend and Observe an ASC 

Meeting 

Email your name, organization and 

contact information to meetings@

asc.gov. 

You may also send a written request 

via U.S. Mail, fax or commercial carrier 

to the Executive Director of the ASC, 

1401 H Street NW., Ste 760, 

Washington, DC 20005. The fax number 

is 202–289–4101. Your request must be 

received no later than 4:30 p.m., ET, on 

the Monday prior to the meeting. 

Attendees must have a valid 

government-issued photo ID and must 

agree to submit to reasonable security 

measures. The meeting space is 

intended to accommodate public 

attendees. However, if the space will not 


tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 191 / Wednesday, October 2, 2013 / Notices 60873 

accommodate all requests, the ASC may 

refuse attendance on that reasonable 

basis. The use of any video or audio 

tape recording device, photographing 

device, or any other electronic or 

mechanical device designed for similar 

purposes is prohibited at ASC meetings. 

Dated: September 26, 2013. 

James R. Park, 

Executive Director. 

[FR Doc. 2013–23985 Filed 10–1–13; 8:45 am] 

BILLING CODE 6700–01–P 

FEDERAL FINANCIAL INSTITUTIONS 

EXAMINATION COUNCIL 

[Docket No. AS13–23] 

Appraisal Subcommittee Meeting 

AGENCY: Appraisal Subcommittee of the 

Federal Financial Institutions 

Examination Council. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with Section 

1104(b) of Title XI of the Financial 

Institutions Reform, Recovery, and 

Enforcement Act of 1989, as amended, 

notice is hereby given that the Appraisal 

Subcommittee (ASC) will meet in closed 

session: 

DATES: October 9, 2013. 

ADDRESSES: 400 7th Street SW., 

Washington, DC 20024. 

SUPPLEMENTARY INFORMATION: 

Location: OCC—400 7th Street SW., 

Washington, DC 20024 

Date: October 9, 2013 

Time: Immediately following the ASC 

open session 

Status: Closed 

Matters To Be Considered 

September 11, 2013 minutes—Closed 

Session 

Preliminary discussion of State 

Compliance Reviews 

Dated: September 26, 2013. 

James R. Park, 

Executive Director. 

[FR Doc. 2013–23986 Filed 10–1–13; 8:45 am] 

BILLING CODE 6700–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

notices are set forth in paragraph 7 of 

the Act (12 U.S.C. 1817(j)(7)). 

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the offices of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than October 

16, 2013. 

A. Federal Reserve Bank of Kansas 

City (Dennis Denney, Assistant Vice 

President) 1 Memorial Drive, Kansas 

City, Missouri 64198–0001: 

1. Glory Burns, Fort Collins, Colorado, 

Robin Isham, Templeton, California, 

Andrea Voss, Chadron, Nebraska, Julie 

Jennings, Lone Tree, Colorado, and R. 

Will Isham, Gordon, Nebraska, 

individually and as trustees of the E. Joy 

Isham Irrevocable Trust, and the RWI 

Marital Deduction Testamentary Trust, 

both of Gordon, Nebraska, all as 

members of the Isham Family Group, to 

retain voting shares of Isham 

Management Company, and thereby 

indirectly retain voting shares of The 

First National Bank of Gordon, both in 

Gordon, Nebraska. 

Board of Governors of the Federal Reserve 

System, September 26, 2013. 

Margaret McCloskey Shanks, 

Deputy Secretary of the Board. 

[FR Doc. 2013–23936 Filed 10–1–13; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

has taken final action in the following 

case: 

Nitin Aggarwal, Ph.D., Medical 

College of Wisconsin and University of 

Wisconsin-Madison: Based on the 

reports of the investigations conducted 

by the Medical College of Wisconsin 

(MCW) and the University of 

Wisconsin-Madison (UW) and 

additional analysis conducted by the 

ORI in its oversight review, ORI found 

that Dr. Nitin Aggarwal, former 

Graduate Student, MCW, and former 

Assistant Scientist, UW, engaged in 

research misconduct in research 

supported by National Heart, Lung, and 

Blood Institute (NHLBI), National 

Institutes of Health (NIH), grants R01 

HL37981, R01 HL54075, and R01 

HL57414. 

ORI found that that the Respondent 

engaged in research misconduct by 

falsifying and/or fabricating PHSsupported data in six (6) figures that 

were included in the following two (2) 

publications, one (1) grant application 

to the American Heart Association 

(AHA), one (1) grant application to NIH, 

and the Respondent’s Ph.D. thesis: 

• Aggarwal, N.T., Pfister, S.L., & 

Campbell, W.B. ‘‘Hypercholesterolemia 

Enhances 15-Lipoxygenase Mediated 

Vasorelaxation and AcetylcholineInduced Hypotension.’’ Arteriosclerosis, 

Thrombosis, and Vascular Biology 

28:2209–2215, 2008 (hereafter the 

‘‘ATVB paper’’). 

• Aggarwal, N.T., Pfister, S.L., 

Gauthier, K.M., Chawengsub, Y., Baker, 

J.E., & Campbell, W.B. ‘‘Chronic hypoxia 

enhances 15-lipoxygenase-mediated 

vasorelaxation in rabbit arteries.’’ 

American Journal of Physiology—Heart 

Circulation Physiology 296:H678–H688, 

2008 (hereafter the ‘‘AJP paper’’). 

• Aggarwal, N.T., Principal 

Investigator (P.I.), National Scientist 

Development grant application to the 

American Heart Association No. 

11SDG7650072, ‘‘Sulfonylurea 

rReceptor-2 splice variant and 

mitochondrial mechanisms for 

cardioprotection and arrhythmia’’ 

(hereafter the ‘‘AHA grant application’’). 

• K99 HL113518–01, ‘‘Mitochondrial 

ATP-sensitive K-channels and 

pharmacological approaches for 

cardioprotection,’’ Aggarwal, Nitin, 

Ph.D., P.I. 

• Aggarwal, N.T. ‘‘Endothelial 15- 

lipoxygenase regulates vasorelaxation 

and blood pressure in rabbits in normal 

and pathological condictions.’’ A 

Dissertation Submitted to the Faculty of 

the Graduate School of Biomedical 

Science of the Medical College of 

Wisconsin in Partial Fulfillment of the 

Requirements for the Degree of Doctor of 

Philosophy, Milwaukee, Wisconsin, 

2008 (hereafter the ‘‘thesis’’). 

Specifically, ORI found that 

Respondent engaged in research 

misconduct by falsifying Western blot 

loading control data by inverting, 

duplicating, and cropping source blot 

films and/or using films from unrelated 

experiments to construct five (5) false 

Western blot figures. In the absence of 

valid blot images, Respondent falsified 

and/or fabricated the corresponding 

quantitative data for summary bar 

graphs and the data statistics in related 

text. Respondent admitted to falsely 

reporting the number of mice reported 

for an experiment reported in Figure 4 


tkelley on DSK3SPTVN1PROD with NOTICES